Research To Practice | Oncology Videos

Featuring an interview with Dr Brady Stein, including the following topics: Case: A man in his late 70s with myelofibrosis (MF) presenting with fatigue and night sweats (0:00) Incidence and severity of fatigue and other symptoms; use of symptom scales to measure severity (3:43) Rapidity of symptom response to ruxolitinib; emerging data with momelotinib (7:34) Novel therapeutic targets for MF: BET, PI3K and BCL2 (13:25) Available data on JAK inhibitors for essential thrombocytosis and polycythemia vera; pathogenesis of pruritus and optimal management (20:31) Clinical pearls on managing splenomegaly, weight loss and other MF symptoms (26:34) Risks of localized therapy for splenomegaly; splenic progression among patients receiving ruxolitinib (30:14) Prevention and management of withdrawal rebound from ruxolitinib; factors to consider in choosing JAK inhibitors for different risk groups (34:17) Myths and misperceptions about MF among community general oncologists (38:26) Management algorithms for transplant-eligible and transplant-ineligible patients (44:32) Current understanding of MF pathophysiology; end-of-life care for patients with MF (50:13) CME information and select publications

Featuring a slide presentation and related discussion from Dr Pamela Kunz, including the following topics: Epidemiology of neuroendocrine tumors (NETs) (0:00) Strategies for the hormonal control of NETs (11:03) Tools for tumor control (17:03) CME information and select publications

Featuring an interview with Dr Pamela Kunz, including the following topics: Increasing incidence of neuroendocrine tumors (NETs); heterogeneity in the clinical presentation of patients with NETs (0:00) Case: A woman in her early 50s newly diagnosed with a metastatic NET; optimal patient workups (5:08) Choosing between observation and treatment for metastatic NETs (9:52) Cardiovascular issues associated with NETs; factors to consider when selecting a somatostatin analogue (14:16) Case: A man in his early 60s with a 5-year history of metastatic small bowel NET; available data with telotristat for carcinoid syndrome diarrhea (21:13) Case: A man in his early 60s with a 2-month history of lower left quadrant cramping, reduced appetite, and weight loss (28:07) Key takeaways about the management of NETs; potential future strategies for treating NETs (33:26) CME information and select publications

Featuring perspectives from Dr Pasi Jänne, including the following topics: Introduction: Journal Club with Pasi A Jänne, MD, PhD — Part 1 (0:00) Case: An Asian man in his late 60s with adenocarcinoma of the lung and pleural effusion with EGFR amplification (PD-L1 20%) — Jennifer L Dallas, MD (12:33) Case: A man in his late 50s with metastatic adenocarcinoma of the lung with discordant EGFR testing results and a new mediastinal lesion after therapy with osimertinib — Rohit Gosain, MD (16:10) Case: A man in his late 40s with metastatic adenocarcinoma of the lung and a brain metastasis with an EGFR exon 19 mutation and disease progression after stereotactic body radiation therapy (SBRT) and osimertinib, now with an ALK mutation by RNA testing (PD-L1 0) — Namrata I Peswani, MD (18:44) Case: A man in his early 50s with Stage III unresectable adenocarcinoma of the lung with an EGFR mutation who receives chemoradiation therapy and consolidation durvalumab, now with metastatic recurrence — Ferdy Santiago, MD (21:51) Case: A man in his early 70s with Stage IIIC large cell neuroendocrine carcinoma of the lung and an EGFR S768I mutation (PD-L1 1%) — Jarushka Naidoo, MB BCH, MHS (28:17) Case: A man in his early 80s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion mutation and disease progression on mobocertinib — Jiaxin (Jason) Niu, MD, PhD (32:15) Case: A woman in her mid 70s with adenocarcinoma of the lung and an EGFR exon 20 insertion mutation with new bone and brain metastases after therapy with osimertinib — Dr Niu (37:11) Journal Club with Dr Jänne — Part 2 (43:02) Case: A woman in her mid 80s with metastatic adenocarcinoma of the lung with an EGFR exon 21 mutation who switched to erlotinib due to osimertinib-related toxicities, now with recurrence at the primary site (PD-L1 10%) — John Yang, MD (55:18) Case: An Asian man in his early 70s with metastatic adenocarcinoma of the lung with an EGFR exon 19 deletion and brain metastases who receives SBRT and osimertinib but develops extracranial biopsy-proven small cell lung cancer progression — Dr Niu (58:35) CME information and select publications

Featuring perspectives from Dr Sagar Lonial, including the following topics: Journal Club with Sagar Lonial, MD — Part 1 (0:00) Case: A man in his late 50s with relapsed t(11;14) multiple myeloma (MM) 17 years after initial induction treatment and ASCT — Rajalaxmi McKenna, MD (16:45) Case: A man in his mid 70s with NDMM receives daratumumab/lenalidomide/dexamethasone in EAA181 clinical trial and develops ileus — Erik Rupard, MD (31:09) Case: A man in his early 80s with NDMM, a borderline performance status and multiple medical comorbidities, including DM, CHF and CKD — Ranju Gupta, MD (35:18) Case: A woman in her late 60s with biochemical progression of del(17p) MM, s/p RVd, ASCT and 1 year of maintenance bortezomib/lenalidomide — Warren S Brenner, MD (38:40) Case: An otherwise healthy man in his mid 70s with refractory MM, s/p 5 prior lines of therapy — Jeremy Lorber, MD (43:36) Faculty Survey (55:05) CME information and select publications

Featuring an interview with Prof Axel Hauschild, including the following topics: Pan-tumor approval of dabrafenib/trametinib; data with adjuvant targeted therapy for melanoma (0:00) Emerging data with encorafenib/binimetinib for Stage II melanoma; switching from dabrafenib/trametinib to encorafenib/binimetinib (5:23) Recent data with ipilimumab/nivolumab versus dabrafenib/trametinib from the DREAMseq trial; using targeted therapy after immunotherapy (9:58) Relationship between tumor mutational burden and response to targeted therapies and immunotherapies; PD-L1 expression and efficacy of immunotherapy alone compared to in combination (15:36) T-cell targets for immunoregulatory antibody therapy; treatment for patients with underlying autoimmune disease (20:23) Influence of corticosteroids on immunotherapy efficacy; adverse event profiles of dabrafenib/trametinib and encorafenib/binimetinib and optimal management (25:13) Case: A man in his early 50s with an ulcerated melanoma metastasis and BRAF mutation (32:05) Case: A woman in her early 40s with BRAF-mutated melanoma and a poor ECOG performance status (41:25) CME information and select publications

Featuring a slide presentation and related discussion from Prof Axel Hauschild, including the following topics: Emerging data with targeted agents for metastatic melanoma (0:00) Current and future roles for immune checkpoint inhibitors in therapy for melanoma (11:13) Comparing targeted agents and immune checkpoint inhibitors (17:34) Current melanoma guidelines and other therapies under investigation (24:09) CME information and select publications

Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics: Prologue (0:00) First-line treatment (3:38) Bispecific antibodies (34:41) CAR T-cell therapy (48:21) CME information and select publications

Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics: Biology of RET Genetic Alterations in Cancer (0:00) Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44) Mechanisms of Action of Selective RET Inhibitors (3:58) Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04) Updated Efficacy and Safety Results with Pralsetinib Therapy for RET-Altered NSCLC (13:14) Mechanisms of Resistance to Selective RET Inhibitors (19:33) CME information and select publications

Featuring an interview with Dr Justin Gainor, including the following topics: Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00) Significance of non-fusion RET abnormalities in NSCLC (3:33) Clinical impact of tumor-agnostic targeted therapy (5:11) Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46) Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24) Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45) Adjuvant therapy for RET-rearranged NSCLC (26:23) Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07) Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40) Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28) CME information and select publications